overgrowth of the gut by the pathogens and finally lead to manifestation of diseases. 48 Colonization by potentially pathogenic germs, due to infection with these bacteria or 49 the use of antibiotics, can be limited or prevented by the administration of probiotic bacteria. 50 The probiotic germs limit the proliferation of pathogenic bacteria by a variety of mechanisms. 51 Among these is secretion of organic acids, bacteriocins, bacteriocin-like substances, as well 52 as the inhibition of the adhesion of pathogenic bacteria to the gut epithelium. Probiotics are 53 available in the form of yeast probiotics containing e.g. S. boulardii or bacterial probiotics. 54 Bacterial probiotics can be further differentiated into simple probiotics (containing only one 55 or a small number of probiotic bacteria) or complex multistrain probiotics (containing a larger 56 number of different probiotic bacteria). Synbiotics contain, in addition to the probiotic 57 component(s), a prebiotic ingredient, e.g., fructooligosaccaride, which can be used by 58 probiotic germs as a source of energy. 59 Probiotics are discussed as alternative treatments or adjuvant therapy for a number of 60 bacterial infections for which use of antibiotics is either not recommended or emerging 61 antibiotic resistance is of concern. Monostrain probiotics containing the yeast S. boulardii [1-62 3] or the bacterium Lc. rhamnosus [4] [5] [6] have been extensively characterized in the scientific 63 literature. While monostrain probiotics are commonly used in medical practice, there is a 64 recent trend to shift to complex multistrain probiotics [7, 8] and/or complex multistrain Complex multistrain synbiotic 89 The complex multistrain synbiotic product is commercially available as Multilac ® 90 Baby (stickpack with a total of 1 x 10 9 cfu of bacteria) and was obtained from Vivatrex 91 GmbH, Martinstr. 10-12, 52062 Aachen, Germany. Each stickpack of the product contains: 92 1.11 x 10 8 cfu Lactobacillus acidophilus 12] 
In-vitro pathogen inhibition experiments 100
Inhibition of E. coli, Shigella spp. and S. typhimurium 101 For the in-vitro pathogen inhibition experiments with E. coli (strain 25922), Shigella 102 spp. and S. typhimurium (strain 14028), the respective pathogen was inoculated on Columbia 103 agar with 5% sheep blood and incubated at 37º C under aerobic conditions for 24 h. were calculated as well as the standard deviations SD. Statistical differences between the 126 inhibition of the three different products was evaluated by using the independent group T-test 127 (significance p<0.01). Tables containing all raw data from the in-vitro pathogen inhibition 128 experiments, the arithmetic means and standard deviations calculated are provided in S1 13.7±1.2 mm (Fig 1) . There was no significant difference between the inhibition by S. 135 boulardii and Lc. rhamnosus (p=0.0125). Inhibition by the complex multistrain symbiotic was 136 significant stronger than the inhibition by the probiotics. P-values compared to S. boulardii 137 and to Lc. rhamnosus were p=0.0005 and p=0.0001, respectively. containing either Lactobacilli or Bifidobacteria [7, 22, [40] [41] [42] [43] [44] [45] . In a recent study comparing the 155 in vitro antagonistic activity of monostrain and multistrain bacterial probiotics against E. coli, 156 it was found that multistrain probiotics exhibited a significantly stronger inhibitory effect than 157 monostrain probiotics [22] . Results from the present study (Fig 1) supports the latter finding, 8 | P a g e 158 as it was also found that a complex mixture of probiotic bacteria (combined with FOS) has a 159 significant stronger inhibitory effect than less complex yeast or bacterial probiotics.
160
Inhibition of Shigella spp. 161 All three tested products inhibited Shigella spp.. Inhibition caused by S. boulardii and 162 Lc. rhamnosus were similar, 5.7±1.5 mm and 5.3±0.6 mm, respectively. The inhibition caused 163 by the complex multistrain synbiotic was 13.7±1.5 mm (Fig 2) . While there was no 164 significant difference between S. boulardii and Lc. rhamnosus inhibitions (p=0.187), the 165 effect of the complex multistrain symbiotic was significant stronger when compared with S. Beneficial effects during Shigella infections have been described for S. boulardii 9 | P a g e 181 [32, 37, 47, 48] , bacterial single-strain probiotics [7, 40, 49] and multistrain probiotics [7] . The 182 present study found that S. boulardii and Lc. rhamnosus exhibit an inhibitory effect on the in 183 vitro growth of Shigella spp.. While the effect of both, the yeast monostrain and the Lc. 184 rhamnosus probiotic, were small and similar in extent, the tested complex multistrain 185 synbiotic product resulted in a significantly stronger growth inhibition. Most food-borne bacterial gastroenteritis is caused by ingestion of food or water contaminated 200 with non-typhoidal Salmonella (NTS). In most cases, NTS is a self-limiting disease that 201 causes mild gastroenteritis. However, there are also cases of persistent NTS, in which the 202 infection and its symptoms manifest for years [50] . The pathology of Salmonella infections is 203 characterized by diarrhea often with heme-positive stool and abdominal pain. Excess 10 | P a g e 204 antibiotic use in years prior to the infection is associated with a higher incidence of NTS.
205
Disruption of the balance of the gut microbiota (e.g., by antibiotics) is discussed as a possible 206 cause. For most of patients an antimicrobial therapy is not indicated. Positive effects on 207 Salmonella infections have been described for S. boulardii [32, 39, 51, 52] , bacterial 208 monostrain probiotics [7, 40, 41, 43, 53, 54] and multistrain probiotics [7, 55] . The present study 209 confirms that S. boulardii and Lc. rhamnosus exhibit growth antagonistic properties against S. 210 typhimurium. However, when the inhibitory effect of the probiotics was compared with that 211 of a complex multistrain synbiotic, it was found that the inhibition by the complex multistrain 212 synbiotic was significantly stronger. The beneficial role of probiotics in the four pathogen infection situations described above 249 remains still not fully understood. However, there is emerging evidence that probiotics might 250 be of benefit as alternative treatments or adjuvant therapies. Both tested probiotics exhibited 12 | P a g e 251 growth inhibiting properties against all four examined pathogens. No difference was found 252 between the size of the inhibitory effect of the yeast monostrain probiotic and that of the 253 bacterial Lc. rhamnosus probiotic. Compared to the probiotics, the complex multistrain 254 synbiotic was found to result in significant stronger in vitro inhibition of the tested pathogens.
255
More clinical research will be needed to characterize the potential benefits of probiotic or 256 synbiotic products in case of infections with E. coli, Shigella spp., S. typhimurium or Cl. 257 difficile. However, results from the present study suggest that testing the effect of complex 258 multistrain synbiotics might be particular interesting to investigate in clinical settings.
